Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of CYP1A2 genetic polymorphisms on the pharmacokinetics of pentoxifylline and its active metabolites.

BMC pharmacology & toxicology - 26 Feb 2026

Guo Lingfang, Sun Xue, Qiu Bo, Bai Wanjun, Du Yabin, Song Haojing

Abstract excerpt

PURPOSE: To investigate whether the CYP1A2 genetic polymorphisms could affect the pharmacokinetics of pentoxifylline and its two active metabolites in Chinese healthy participants. METHODS: Forty-six healthy Chinese volunteers were administered a single 400 mg oral dose of pentoxifylline. The plasma concentrations of pentoxifylline and its active metabolites were quantified using LC-MS/MS. The CYP1A2 genotypes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP1A2
Share to East Asian People

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Pharmacogenomic Variants

Share to Polymorphism, Single Nucleotide

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 41749399
DOI: 10.1186/s40360-026-01106-2
PMCID: PMC13041349

Genes

CYP1A2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of CYP1A2 genetic polymorphisms on the pharmacokinetics of pentoxifylline and its active metabolites.PMID 41749399Read ↗

Effects of ABC transporter polymorphism on the pharmacokinetics of pentoxifylline and its active metabolites in healthy Chinese subjects.Semantic proximity Read ↗

Effect of SLC22A1 polymorphism on the pharmacokinetics of proguanil in Korean: A semi-physiologic population pharmacokinetic approach.Semantic proximity Read ↗

Precision Medicine in Toxicology.Semantic proximity Read ↗

The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals.Semantic proximity Read ↗

Evaluation of drug-drug interaction between Suraxavir Marboxil (GP681) and itraconazole, and assessment of the impact of gene polymorphismSemantic proximity Read ↗

A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles.Semantic proximity Read ↗

Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level.Semantic proximity Read ↗

An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure.Semantic proximity Read ↗

The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects.Semantic proximity Read ↗

CYP2D6 phenotype-specific codeine population pharmacokinetics.Semantic proximity Read ↗

Clinical Pharmacokinetics and the Impact of Genetic Polymorphism on a CYP2C19 Substrate, BMS-823778, in Healthy Subjects.Semantic proximity Read ↗

Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.